Novartis’s Entresto PARAGON-HF Miss Puts Large Commercial Opportunity At Risk
Entresto has narrowly failed to hit the primary endpoint in a Phase III trial in heart failure with preserved ejection fraction, a potentially lucrative indication with no approved treatments.
You may also be interested in...
Zolgensma generated $160m in the third quarter, a strong launch for the gene therapy's first full quarter on the market.
Sacubitril/valsartan combination sales surge in India driving growth in the cardiac care segment even as Novartis and challenger Natco slug it out in court over alleged patent infringement charges.
AstraZeneca’s SGLT2 inhibitor has grabbed attention for its potential role in chronic heart failure patients, with or without type 2 diabetes, following initial results from the DAPA-HF study.